U.S. Hedge Fund Seeks Board Shake-Up at Toshiba (The Wall Street Journal) TOKYO—New York-based hedge fund King Street Capital Management LP has proposed...
Keep Reading →
August 31 - Hedge Funds, Insider Trading - Comments
We are now into the final quarter of 2016, and there looks set to be plenty of activity across the biotech space before the year draws to a close. Companies...
Keep Reading →
October 5 - News - Comments
The importance of hedge fund sentiment is not only reflected by the long positions that these firms take in high flying companies, but also how quickly...
Keep Reading →
May 8 - Hedge Funds, News - Comments
Three years ago, cancer immunotherapy was the hottest thing in biotech, as Dendreon Corporation (NASDAQ:DNDN)‘s Provenge earned approval from the...
Keep Reading →
September 12 - News - Comments
If you were to ask many market players, hedge funds are assumed to be overrated, old investment vehicles of a forgotten age. Although there are more than...
Keep Reading →
September 4 - News - Comments
What’s a smart Puma Biotechnology Inc (NYSE:PBYI) investor to do? In today’s marketplace, there are dozens of methods market participants can...
Keep Reading →
September 3 - News - Comments
Since Dendreon Corporation (NASDAQ:DNDN) reported its second-quarter earnings, the stock has declined 40%. Following the quarter, analysts from Wedbush...
Keep Reading →
August 28 - News - Comments
In today’s marketplace, there are tons of gauges market participants can use to track their holdings. A duo of the most innovative are hedge fund and...
Keep Reading →
August 28 - News - Comments
MannKind Corporation (NASDAQ:MNKD) has gotten one of the biggest votes of confidence we’ve seen from the smart money, out of the entire stock market...
Keep Reading →
August 22 - News - Comments
Cancer is the target of a number of different biotech companies. Out of this lot, I consider Seattle Genetics, Inc. (NASDAQ:SGEN) to be one of the star...
Keep Reading →
August 6 - News - Comments
The U.S. is the largest market of biotechnology products in the world. There are more than 1,300 companies involved in the research and development of...
Keep Reading →
July 18 - News - Comments
Celldex Therapeutics, Inc. (NASDAQ:CLDX), the first antibody-based immunotherapy company, has been a strong buy recommended by several analysts for some...
Keep Reading →
July 17 - News - Comments
According to IBISWorld, revenue of global biotechnology companies will surge to $262 billion this year, up by 12.7%, year-over-year. This growth is due...
Keep Reading →
July 16 - News - Comments
Biotech’s the biggest boom-or-bust business on the market, with regulatory approvals and clinical trial results routinely sending stocks hurtling...
Keep Reading →
July 15 - News - Comments
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry. Perhaps you already own one, or maybe...
Keep Reading →
July 12 - News - Comments
While many American skies were lit up with fireworks this week, the stock market also saw its share of pops, sizzles, and bangs. Here are three health...
Keep Reading →
July 8 - News - Comments
There are many biotech stocks that target cancer, but what is good about Celldex Therapeutics, Inc. (NASDAQ:CLDX) is that it is targeting many therapeutic...
Keep Reading →
July 3 - News - Comments
While a company is in the clinical phase of development, there are roughly four catalysts that could move the stock higher. 1. Expansion of intellectual...
Keep Reading →
July 1 - News - Comments
With more than 230,000 women diagnosed with breast cancer in the U.S. annually – and Roche’s Herceptin producing annual sales of more than $5 billion...
Keep Reading →
June 17 - News - Comments
The cancer world has been abuzz after an exciting ASCO conference. Bristol Myers Squibb Co. (NYSE:BMY) presented really promising updates for its PD-...
Keep Reading →
June 14 - News - Comments
A 2011 Nobel Prize in Physiology and Medicine is certainly impressive. Using a novel cancer treatment on yourself is both impressive and courageous. ...
Keep Reading →
June 10 - News - Comments
Is Puma Biotechnology Inc (NYSE:PBYI) a buy here? Hedge funds are betting on the stock. The number of bullish hedge fund bets improved by 2 lately. In...
Keep Reading →
June 10 - News - Comments
Three biotech companies are making themselves heard in the stock market. They are making a mark in the life sciences space with their unique mix of science...
Keep Reading →
May 1 - News - Comments
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has seen a decrease in enthusiasm from smart money in recent months. According to most investors, hedge funds...
Keep Reading →
April 8 - News - Comments
There has been a significant rally in the share price of Celldex Therapeutics, Inc. (NASDAQ:CLDX) recently. The stock is still showing positive momentum...
Keep Reading →
March 27 - News - Comments
The Dow set an all-time high, but it still was up only 2% for the week. If you want returns to really get excited about, look no further than the health...
Keep Reading →
March 10 - News - Comments
What’s better than momentum? Mo’ momentum. Let’s take a closer look at five of this past week’s biggest scorchers. Company Feb...
Keep Reading →
February 24 - News - Comments
There’s power in positive thinking. The late author Norman Vincent Peale made plenty of money off that philosophy. Some investors made lots of money...
Keep Reading →
February 22 - News - Comments
